{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T04:30:11Z","timestamp":1768710611986,"version":"3.49.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"am","delay-in-days":322,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011783","name":"University of Notre Dame Mike and Josie Harper Cancer Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011783","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["RO1CA109545"],"award-info":[{"award-number":["RO1CA109545"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UO1CA236979"],"award-info":[{"award-number":["UO1CA236979"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jconrel.2024.09.014","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T13:46:45Z","timestamp":1726753605000},"page":"438-453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Combination non-targeted and sGRP78-targeted nanoparticle drug delivery outperforms either component to treat metastatic ovarian cancer"],"prefix":"10.1016","volume":"375","author":[{"given":"Jenna N.","family":"Sjoerdsma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily K.","family":"Bromley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaeho","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyvette","family":"Hilliard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin","family":"Horgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyoyeon","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Bektas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Omstead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanyel","family":"Kiziltepe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Sharon","family":"Stack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basar","family":"Bilgicer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2015","key":"10.1016\/j.jconrel.2024.09.014_bb0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7150\/jca.7810","article-title":"Current approaches and challenges in managing and monitoring treatment response in ovarian cancer","volume":"5","author":"Marcus","year":"2014","journal-title":"J. Cancer"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0015","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/02841860151116420","article-title":"A systematic overview of chemotherapy effects in ovarian cancer","volume":"40","author":"H\u00f6gberg","year":"2001","journal-title":"Acta Oncol. (Madr)"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0020","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherpy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0025","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdq368","article-title":"The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer","volume":"21","author":"Bookman","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0030","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13048-020-00736-2","article-title":"Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer","volume":"14","author":"Yuan","year":"2021","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0040","first-page":"152","article-title":"Comparing outcomes in patients with recurrent or refractory ovarian cancer managed with 1 of 2 versions of pegylated liposomal doxorubicin at an academic medical center","volume":"8","author":"Amerine","year":"2018","journal-title":"J. Hematol. Oncol. Pharm."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/898146","article-title":"Clinical trials with pegylated liposomal doxorubicin in the treatment of ovarian cancer","volume":"2013","author":"Pisano","year":"2013","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0050","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1634\/theoncologist.2013-0126","article-title":"The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials","volume":"18","author":"Gibson","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0055","doi-asserted-by":"crossref","first-page":"7768","DOI":"10.3390\/ijms21207768","article-title":"Recycling the purpose of old drugs to treat ovarian cancer","volume":"21","author":"Nunes","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0060","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2217\/fon-2019-0042","article-title":"Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer","volume":"16","author":"Haunschild","year":"2020","journal-title":"Future Oncol."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0065","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.semcancer.2021.08.011","article-title":"Chemotherapy resistance in epithelial ovarian cancer: mechanisms and emerging treatments","volume":"77","author":"Marchetti","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121913","article-title":"Disease-driven engineering of peptide-targeted DM1 loaded liposomal nanoparticles for enhanced efficacy in treating multiple myeloma by exploring DM1 prodrug chemistry","volume":"292","author":"Khan","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0075","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.taap.2013.09.003","article-title":"Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability","volume":"273","author":"Poon","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0080","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1158\/0008-5472.CAN-20-3822","article-title":"Transient competitive inhibition bypasses the binding site barrier to improve tumor penetration of trastuzumab and enhance T-DM1 efficacy","volume":"81","author":"Bordeau","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26195847","article-title":"An insight into FDA approved antibody-drug conjugates for cancer therapy","volume":"26","author":"Tong","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0090","first-page":"113","article-title":"A therapeutic trial of maytansine","volume":"1","author":"Blum","year":"1978","journal-title":"Cancer Clin. Trials"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0095","first-page":"435","article-title":"Maytansine: a phase I study of an ansa macrolide with antitumor activity","volume":"62","author":"Blum","year":"1978","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0100","first-page":"1115","article-title":"Phase II study of maytansine in patients with advanced lymphomas: an eastern cooperative oncology group pilot study","volume":"64","author":"Rosenthal","year":"1980","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0105","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0110","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody\u2013drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0115","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1021\/jz201682z","article-title":"Enhancement of antibody selectivity via bicyclic complex formation","volume":"3","author":"Stefanick","year":"2012","journal-title":"J. Phys. Chem. Lett."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0120","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1039\/C8NR09431D","article-title":"Dual-receptor targeted strategy in nanoparticle design achieves tumor cell selectivity through cooperativity","volume":"11","author":"Stefanick","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0125","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jconrel.2020.04.010","article-title":"Engineering peptide-targeted liposomal nanoparticles optimized for improved selectivity for HER2-positive breast cancer cells to achieve enhanced in vivo efficacy","volume":"322","author":"Kim","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0130","doi-asserted-by":"crossref","first-page":"11672","DOI":"10.1039\/D0NR02133D","article-title":"Identification of a moderate affinity CD22 binding peptide and in vitro optimization of peptide-targeted nanoparticles for selective uptake by CD22+ B-cell malignancies","volume":"12","author":"Kim","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0135","doi-asserted-by":"crossref","DOI":"10.1039\/D3NR00800B","article-title":"A nanotherapeutic approach to selectively eliminate metastatic breast cancer cells by targeting cell surface GRP78","volume":"15","author":"Shin","year":"2023","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-60269-y","article-title":"Cell surface GRP78 promotes stemness in normal and neoplastic cells","volume":"10","author":"Conner","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0145","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/iub.2502","article-title":"Glucose-regulated protein (GRP78) is an important cell surface receptor for viral invasion, cancers, and neurological disorders","volume":"73","author":"Gonzalez-Gronow","year":"2021","journal-title":"IUBMB Life"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0150","doi-asserted-by":"crossref","first-page":"107176","DOI":"10.18632\/oncotarget.22412","article-title":"Circulating GRP78 antibodies from ovarian cancer patients: a promising tool for cancer cell targeting drug delivery system?","volume":"8","author":"Van Hoesen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0155","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/s41598-020-59116-x","article-title":"Clinicopathological significance of endoplasmic reticulum stress proteins in ovarian carcinoma","volume":"10","author":"Samanta","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0160","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00965-4","article-title":"In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma","volume":"13","author":"Omstead","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0165","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1039\/D1NR05357D","article-title":"Identification and optimization of tunable endosomal escape parameters for enhanced efficacy in peptide-targeted prodrug-loaded nanoparticles","volume":"14","author":"Mejia","year":"2022","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0170","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1021\/acsbiomaterials.2c00100","article-title":"Liposomal targeting modifies endosomal escape: design and mechanistic implications","volume":"8","author":"Mejia","year":"2022","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0175","doi-asserted-by":"crossref","first-page":"25174","DOI":"10.1021\/acsami.8b08125","article-title":"Paclitaxel-loaded self-assembled lipid nanoparticles as targeted drug delivery systems for the treatment of aggressive ovarian cancer","volume":"10","author":"Zhai","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11671-021-03628-6","article-title":"Nanoparticles for cancer therapy: current progress and challenges","volume":"16","author":"Gavas","year":"2021","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0185","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1158\/0008-5472.CAN-16-1272","article-title":"CRISPR\/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high-grade serous carcinoma","volume":"76","author":"Walton","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0190","doi-asserted-by":"crossref","first-page":"8115","DOI":"10.1021\/nn4033954","article-title":"Enhanced cellular uptake of peptide-targeted nanoparticles through increased peptide hydrophilicity and optimized ethylene glycol peptide-linker length","volume":"7","author":"Stefanick","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0195","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1021\/nn305663e","article-title":"A systematic analysis of peptide linker length and liposomal polyethylene glycol coating on cellular uptake of peptide-targeted liposomes","volume":"7","author":"Stefanick","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0200","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.anai.2022.04.003","article-title":"Determination of immunogenic epitopes in major house dust mite allergen, Der p 2, via nanoallergens","volume":"129","author":"Sjoerdsma","year":"2022","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0205","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1039\/c3an00680h","article-title":"Functionalized liposome purification via liposome extruder purification (LEP)","volume":"138","author":"Alves","year":"2013","journal-title":"Analyst"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0210","article-title":"Quantitation of intra-peritoneal ovarian cancer metastasis","volume":"2016","author":"Lewellen","year":"2016","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0215","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/0008-5472.CAN-19-1601","article-title":"Host Wnt5a potentiates microenvironmental regulation of ovarian cancer metastasis","volume":"80","author":"Asem","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0220","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.neo.2018.03.007","article-title":"Aging increases susceptibility to ovarian cancer metastasis in murine allograft models and alters immune composition of peritoneal adipose tissue","volume":"20","author":"Loughran","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0225","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1073\/pnas.1500128112","article-title":"Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors","volume":"112","author":"Mandelin","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0230","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.8210","article-title":"Discovery and characterization of Isofistularin-3, a marine brominated alkaloid, as a new DNA demethylating agent inducing cell cycle arrest and sensitization to TRAIL in cancer cells","volume":"7","author":"Florean","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0235","article-title":"Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer","volume":"2016","author":"Jaaback","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0240","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1200\/JCO.2015.61.4776","article-title":"Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian Cancer","volume":"33","author":"Wright","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0245","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/carcin\/21.4.585","article-title":"Development of a syngeneic mouse model for events related to ovarian cancer","volume":"21","author":"Roby","year":"2000","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0250","doi-asserted-by":"crossref","first-page":"11913","DOI":"10.1038\/s41598-020-68639-2","article-title":"Ascites-induced compression alters the peritoneal microenvironment and promotes metastatic success in ovarian cancer","volume":"10","author":"Asem","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0255","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1158\/0008-5472.CAN-15-0706","article-title":"Obesity contributes to ovarian cancer metastatic success through increased lipogenesis, enhanced vascularity, and decreased infiltration of M1 macrophages","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-015-0669-x","article-title":"Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer","volume":"18","author":"Verma","year":"2016","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0265","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1182\/blood.V84.7.2221.2221","article-title":"Lymphocyte depletion during treatment with intensive chemotherapy for cancer","volume":"84","author":"Mackall","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-11-147","article-title":"Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer","volume":"11","author":"Lavou\u00e9","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0275","first-page":"198","article-title":"Pattern of CD4 T-lymphocyte values in cancer patients on cytotoxic therapy","volume":"3","author":"Madu","year":"2014","journal-title":"Ann. Med. Health Sci. Res."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24129804","article-title":"Advanced glycation end products as a potential target for restructuring the ovarian cancer microenvironment: a pilot study","volume":"24","author":"Harper","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0285","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3389\/fimmu.2020.00924","article-title":"Dendritic cells and their role in immunotherapy","volume":"11","author":"Gardner","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0290","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41423-021-00741-5","article-title":"Dendritic cells in cancer immunology","volume":"19","author":"Murphy","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0295","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081946","article-title":"The role of macrophages in cancer development and therapy","volume":"13","author":"Cendrowicz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0300","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/bjc.1988.36","article-title":"Macrophages in human breast disease: a quantitative immunohistochemical study","volume":"57","author":"Kelly","year":"1988","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2024.09.014_bb0305","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1189\/jlb.0609385","article-title":"Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation","volume":"86","author":"Solinas","year":"2009","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00614","article-title":"Molecular mechanisms that influence the macrophage M1-M2 polarization balance","volume":"5","author":"Wang","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-021-02089-2","article-title":"New insights into M1\/M2 macrophages: key modulators in cancer progression","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0320","doi-asserted-by":"crossref","DOI":"10.1177\/2042098620915058","article-title":"Risk of hepatotoxicity with trastuzumab emtansine in breast cancer patients: a systematic review and meta-analysis","volume":"11","author":"Cobert","year":"2020","journal-title":"Ther. Adv. Drug Saf."},{"issue":"SEP","key":"10.1016\/j.jconrel.2024.09.014_bb0325","first-page":"256","article-title":"Getting to know ovarian cancer ascites: Opportunities for targeted therapy-based translational research","volume":"3","author":"Ahmed","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0330","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0335","article-title":"A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier","volume":"31","author":"Fujimori","year":"1990","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0340","first-page":"5144","article-title":"Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier","volume":"52","author":"Juweid","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0345","first-page":"4776","article-title":"An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a \u201cbinding site barrier,\u201d","volume":"51","author":"van Osdol","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0350","first-page":"2747s","article-title":"Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the \u201cbinding site barrier,\u201d","volume":"52","author":"Weinstein","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.09.014_bb0355","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924006242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924006242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T13:06:56Z","timestamp":1745586416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924006242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":71,"alternative-id":["S0168365924006242"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.09.014","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination non-targeted and sGRP78-targeted nanoparticle drug delivery outperforms either component to treat metastatic ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}